Physician profile
Michael P Conroy
NPI 1003891052
$15,221.72
in general payments reported to CMS, 2019-2025
27 companies · $808 in 2025
The $808 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $8,429 · 2021: $560 · 2022: $2,453 · 2023: $951 · 2024: $1,282 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,954 · Education: $85.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,954.47 |
| Education | $85.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $9,718.90 | 2019-2024 | |
| Abbvie INC. | $1,835.15 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $727.91 | 2019-2025 | |
| Genzyme Corporation | $475.27 | 2019-2025 | |
| Galderma Laboratories, L.P. | $371.48 | 2020-2025 | Nemluvio |
| Prugen, INC. Pharmaceuticals | $347.53 | 2019-2020 | |
| Janssen Biotech, INC. | $287.31 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $252.20 | 2023-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $218.39 | 2022-2024 | Vtama |
| Incyte Corporation | $187.15 | 2023-2024 | Opzelura |
| Lilly USA, LLC | $170.75 | 2020-2023 | Olumiant, Taltz |
| E.R. Squibb & Sons, L.L.C. | $87.26 | 2021-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $79.01 | 2019-2023 | Ilumya |
| Verrica Pharmaceuticals INC. | $75.96 | 2024 | Ycanth |
| Organon LLC | $70.59 | 2025 | Vtama |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $45.80 | 2024 | Zoryve |
| Almirall LLC | $40.40 | 2025 | Seysara |
| Journey Medical Corporation | $33.72 | 2019-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $33.59 | 2019-2024 | Cabtreo |
| Leo Pharma INC. | $26.27 | 2023 | Adbry |
| Genentech USA, INC. | $25.10 | 2019 | |
| Vyne Pharmaceuticals INC. | $23.73 | 2021 | |
| Epi Health, LLC | $22.12 | 2019 | |
| Aurinia Pharma U.S., INC. | $20.52 | 2023 | Lupkynis |
| Biofrontera INC. | $17.02 | 2025 | Ameluz |
| Ucb, INC. | $16.69 | 2025 | Bimzelx |
| Smith+Nephew, INC. | $11.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Conroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.